---
title: CRO Daily News — September 17, 2026
slug: daily-news-2026-09-17-cro
site: cro
post_kind: news
byline: BioBM
description: September 17 CRO daily: Oncodesign Services and Nexus BioQuest Form Integrated Preclinical Partnership; Quotient Sciences Demonstrates AI-Driven Formulation…
canonical_url: https://www.cro.directory/posts/daily-news-2026-09-17-cro
published_at: 2026-09-17T23:59:46.376Z
last_updated: 2026-09-18T00:02:20.158Z
---

### [Oncodesign Services](/companies/oncodesign-services) and [Nexus BioQuest](/companies/nexus-bioquest) Form Integrated Preclinical Partnership
- [Oncodesign Services](/companies/oncodesign-services) (Dijon, France) and [Nexus BioQuest](/companies/nexus-bioquest) (Bristol, UK) have partnered to offer combined in vivo oncology and in vitro immunology preclinical services, eliminating the need for biotech sponsors to manage separate vendor relationships.
- Oncodesign brings AAALAC-accredited BSL1/2/3 pharmacology infrastructure including radiopharmaceuticals, imaging, and IND-enabling services; Nexus BioQuest contributes human primary cell-based assay platforms for immuno-oncology and autoimmunity across small molecules, biologics, vaccines, and cell therapies.
- The integrated model targets emerging biotech companies lacking resources to evaluate and manage multiple specialist CROs, particularly for immuno-oncology, cell therapy, and next-generation biologics programs requiring complementary in vivo and in vitro expertise.

**Operational Impact**

[Oncodesign Services](/companies/oncodesign-services)' integrated partnership with [Nexus BioQuest](/companies/nexus-bioquest) consolidates preclinical oncology and immunology capabilities, reducing vendor management overhead for sponsors and potentially increasing contract value per relationship for both CROs.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cro-news/oncodesign-services-and-nexus-bioquest-partner-to-give-biotech-sponsors-a-clearer-route-to-specialist-preclinical-cro-expertise)*

---

### Quotient Sciences Demonstrates AI-Driven Formulation Selection in Clinical Trial
- Quotient Sciences' proprietary AI algorithm selected modified-release formulation compositions and doses in a live clinical trial, reaching pharmacokinetic targets within three dosing periods.
- The algorithm screened one-third fewer formulations than conventional methods in prior laboratory work and learned human pharmacokinetic relationships quickly enough to potentially reduce clinical testing timelines for future modified-release programs.

**Operational Impact**

Quotient Sciences' demonstrated AI-driven formulation optimization may reduce clinical trial cycles and screening burden for sponsors developing modified-release drugs, differentiating the CRDMO's early-development service offering.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/quotient-sciences-reports-ai-clinical-trial-milestone)*

## References

1. [PharmaSource RSS — Oncodesign Services and Nexus BioQuest Form Integrated Preclinical Partnership](https://pharmasource.global/content/news/cro-news/oncodesign-services-and-nexus-bioquest-partner-to-give-biotech-sponsors-a-clearer-route-to-specialist-preclinical-cro-expertise)
2. [Contract Pharma Breaking News RSS — Quotient Sciences Demonstrates AI-Driven Formulation Selection in Clinical Trial](https://www.contractpharma.com/breaking-news/quotient-sciences-reports-ai-clinical-trial-milestone)

Source: https://www.cro.directory/posts/daily-news-2026-09-17-cro